Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Post by Iconic25on Jan 27, 2021 12:22pm
222 Views
Post# 32399620

It's LEGAL

It's LEGAL
Sponsored post:
 
Plant-based product is readily obtainable in most parts of the United States, though its exact legal status is in flux. All 50 states have laws legalizing plant-based product with varying degrees of restriction, and while the federal government still considers plant-based product in the same class as marijuana, it doesn’t habitually enforce against it. 
 
In December 2015, the FDA eased the regulatory requirements to allow researchers to conduct plant-based product trials. Currently, many people obtain plant-based product online without a medical cannabis license. The government’s position on plant-based product is confusing, and depends in part on whether the plant-based product comes from hemp or marijuana. The legality of plant-based product is expected to change, as there is currently bipartisan consensus in Congress to make the hemp crop legal which would, for all intents and purposes, make plant-based product difficult to prohibit. Check disclaimer on profile and Landing Page.
<< Previous
Bullboard Posts
Next >>